Bringing you the latest cutting-edge research and commentary in bioscience.

Cell & Gene Therapy Insights

Cell & Gene Therapy Insights

Interview
Spotlight Article

Targeting lung damage in COVID-19 patients with CD34+ cell therapy

Clinical development strategy, tools and trial designs

Doug Losordo

DOUG LOSORDO is Executive Vice President, Global Head of Research and Development and Chief Medical Officer of Caladrius Bi-osciences. Dr Losordo’s career has been dedicated to the development of novel therapeutics aimed at the reversal of chronic conditions such as refractory angina, critical limb ischemia, coronary microvascular dysfunction, and heart failure. His guiding principle has been that the restoration of health should be our goal, not the management of on-going disease. He has developed clinical programs in gene therapy and cell-based tissue repair targeting myocardial ischemia, diabetic neuropathy, refractory angina, critical limb ischemia, severe claudication, coronary microvascular dysfunction and most recently COVID-19 lung damage.

DOI: 10.18609/cgti.2020.087
Citation: Cell & Gene Therapy Insights 2020; 6(5), 747–753
Open access
This content is restricted to registered users. Click here to Register or Login here.
Twitter IconVisit Our Blog